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Abstract
Background: Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this
prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcitabine as
adjuvant treatment in patients with resected BTC.
Methods: Patients initially received gemcitabine 1000 mg/m2 alone on days 1, 8 and 15 every 28-days for a total of
six cycles (single agent cohort), and after protocol amendment a combination therapy with gemcitabine 1000 mg/m2
and cisplatin 25 mg/m2 on days 1 and 8 was administered every 21 days for a total of eight cycles (combined regimen
cohort). Treatment was planned to start within eight weeks after curative intent resection. Adverse events, disease-free
survival and overall survival were assessed.
Results: Overall 30 patients were enrolled in the study from August 2008 and last patient was enrolled at 2nd
December 2014. The follow-up of the patients ended at 31st December 2016. The first 9 patients received single-agent
gemcitabine. The interim analysis met the predefined feasibility criteria and, from September 2010 on, the second
group of 21 patients received the combination of cisplatin plus gemcitabine. In the single-agent cohort with
gemcitabine the median relative dose intensity (RDI) was 100% (IQR 88.3–100). Patients treated with the combination
cisplatin-gemcitabine received an overall median RDI of 100% (IQR 50–100) for cisplatin and 100% (IQR 75–100) for
gemcitabine respectively. The most significant non-hematological adverse events (grade 3 or 4) were fatigue (20%),
infections during neutropenia (10%), and two cases of biliary sepsis (7%). Abnormal liver function was seen in 10% of
the patients. One patient died due to infectious complications during treatment with cisplatin and gemcitabine. The
median disease-free survival (DFS) was 14.9 months (95% CI 0–33.8) with a corresponding 3-year DFS of 43.1 ± 9.1%.
The median overall survival (OS) was 40.6 months (95% CI 18.8–62.3) with a 3-year OS of 55.7 ± 9.2%. No statistically
significant differences in survival were seen between the two treatment cohorts.
Conclusion: Adjuvant chemotherapy with gemcitabine with or without cisplatin was well tolerated and resulted in
promising survival of the patients.
Trial registration: The study was retrospectively registered on 25th June 2009 at clinicaltrials.gov (NCT01073839).
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Background
Biliary tract cancer (BTC) arises from the biliary epithelium
of intra- and extrahepatic bile ducts and the gallbladder.
The incidence of intrahepatic cholangiocarcinomas has in-
creased steadily in the last years with rising mortality rates,
whereas the incidence of extrahepatic cholangiocarcinomas
remained stable [1, 2].
Surgery is the only curative treatment for BTC
patients, but only a minority of patients are cured [3].
Patients with cholangiocarcinoma have five-year survival
rates of up to 20% for proximal lesions and 20–30% for
distal lesions [4]. The prognosis for patients with gall-
bladder cancer is also unfavourable with overall five-year
survival rates of less than 5%, with outcome depending
largely on the stage of the disease at diagnosis [5]. The
unfavourable prognosis of BTC provides the rationale to
identify effective adjuvant treatment strategies for this
disease. Two adjuvant phase III trials with different
chemotherapy regimens, including single-agent gemcita-
bine, had been reported in patients with either resected
gallbladder cancer or ampullary cancer, but they were
not able to demonstrate a clear survival advantage [6–8].
One meta-analysis [9] evaluating the impact of adjuvant
treatment with systemic chemotherapy, radiation, or
combined chemoradiation in patients after BTC resec-
tion suggested a benefit for high-risk patients with posi-
tive lymph nodes or positive resection margins [10].
Single-agent chemotherapy with gemcitabine [11] has
been the standard of care in the treatment of inoperable
adenocarcinoma of the pancreas prior to more effica-
cious regimens such as FOLFIRINOX and gemcitabine
plus nab-paclitaxel. Oettle and colleagues have shown
that adjuvant chemotherapy with gemcitabine after
macroscopic complete resection of pancreatic cancer
prolongs disease free and overall survival compared to
observation alone [12]. Since the biliary tract is being
considered histologically related to the pancreatic duct
system, gemcitabine has often been used as monother-
apy in various smaller trials for the treatment of inoper-
able BTC with promising results [13–15].
A few years ago, new data for inoperable BTC became
available [16]. In a randomized controlled phase 3 trial
(ABC-02) cisplatin plus gemcitabine was compared to
gemcitabine alone for locally advanced or metastatic bil-
iary tract cancer. The median overall survival could be
prolonged for almost four months from 8.1 months to
11.7 months with the combination regimen. In addition,
the rate of tumor control among patients in the
cisplatin-gemcitabine group was significantly increased
(81.4% vs. 71.8%, p = 0.049) [16]. Both regimens were
feasible with similar rates of adverse events in both
groups, with the exception of increased neutropenia in the
combination arm, which was not associated with an in-
creased rate of infections. Based on this study, cisplatin
plus gemcitabine is being considered the new practice
standard for patients with inoperable biliary tract cancer.
We conducted this prospective, non-randomized study
for patients undergoing macroscopic complete resection
of BTC. Patients were initially treated with gemcitabine
alone, and, after publication of the previous mentioned
ABC-02 trial [13], we amended the protocol and added
cisplatin to gemcitabine. We aimed to assess the feasibil-
ity of this adjuvant treatment in resected patients and its
efficacy in terms of overall and disease free survival.
Methods
This trial was a prospective, single-arm phase II study
conducted at the University Hospital Zurich in
Switzerland. At the time of study conduct, no standard
adjuvant treatment was yet established for cholangiocar-
cinoma, but gemcitabine had been established as adju-
vant standard of care for resected pancreatic cancer
shortly before by Oettle and colleagues. Based on these
data and some smaller and retrospective data describing
a benefit for gemcitabine in advanced cholangiocarci-
noma, we chose this single agent treatment initially. The
primary endpoints were safety and feasibility of adjuvant
chemotherapy with the first patient cohort receiving
gemcitabine as single-agent treatment and, after protocol
amendment, the second patient cohort receiving the
combination of cisplatin plus gemcitabine. After treat-
ment of the first 11 patients, an interim safety analysis
was planned, and the trial would have been stopped
prematurely based on safety evaluations. Secondary
endpoints were completion of treatment, adverse events
according to CTCAE version 3.0, disease-free survival
(DFS), and overall survival (OS). In addition, a separate
analysis of the outcome in patients treated with gemcita-
bine alone (single agent cohort) and patients treated
with cisplatin and gemcitabine combined (combined
regimen cohort) was performed (Fig. 1). The trial started
during August 2008 with first resection of BTC and
ended by the cut-off date of patient’s follow up at 31st
December 2016.
Ethics approval and consent to participate
The study was conducted after obtaining approval from
the local ethical committee (ethical number KEK Zurich
1442) at 15th January 2008 and Swissmedic by 2nd April
2008. First patient was included at 4th August 2008.
Written informed consent was obtained from all patients
in accordance with the Declaration of Helsinki. The
study was retrospectively registered on 25th June 2009
at clinicaltrials.gov, as it was not yet obligatory at the
time of trial start according to national specifications
(NCT01073839).
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Eligibility criteria
Patients diagnosed with cholangiocellular carcinoma
who underwent curative intent tumor resection were
enrolled in this study at the Department of Oncology,
University Hospital Zurich. The main eligibility criteria
included the following: Histologically or cytologically
confirmed adenocarcinoma of the biliary tract (intrahe-
patic, extrahepatic, gallbladder); resection of the tumor
with curative intention up to 8 weeks before start of
chemotherapy; written informed consent; health status:
WHO performance status (PS) 0–1; age > 18 years; ad-
equate renal function (creatinine clearance ≥60 ml/min,
calculated according to the formula of Cockroft-Gault);
adequate hepatic function (bilirubin ≤3 x LUN, AP ≤ 5 x
LUN, ASAT ≤5 x LUN); adequate hematologic function:
neutrophils ≥1.5 × 109/l, platelets ≥100 × 109/l, Hb ≥
9,5 mg/dl.
Patients were excluded in case of: Pregnancy or breast-
feeding women, previous malignancy within 5 years or
concomitant malignancy except non-melanomatous skin
cancer or adequately treated in situ cervical cancer,
neutrophil count <1000/μl, platelet count <100,000/μl,
hemoglobin level < 9,5 mg/dl, bilirubin >3 x LUN, ALAT
>5 x LUN, ASAT >5 x LUN, creatinine clearance <60 ml/
min, calculated according to the formula of Cockroft-
Gault, prior chemotherapy with gemcitabine, severe or
uncontrolled cardiovascular disease (congestive heart fail-
ure NYHA III or IV, unstable angina pectoris, history of
myocardial infarction in the last 3 months, significant ar-
rhythmias), psychiatric disorder precluding understanding
of information of trial related topics and giving informed
consent, active uncontrolled infection, pre-existing per-
ipheral neuropathy (> grade 1), serious underlying medical
condition (judged by the investigator) which could impair
the ability of the patient to participate in the trial (e.g. un-
controlled diabetes mellitus, active autoimmune disease),
concurrent treatment with other experimental drugs or
other anti-cancer therapy; treatment in a clinical trial
within 30 days prior to trial entry, known hypersensitivity
to the study drug.
Treatment schedule
According to the initial protocol version, the first
patients enrolled received gemcitabine at a dose of
1000 mg/m2 as a 30-min infusion on days 1, 8 and 15
every 28 days for a total of 6 cycles (24 weeks in total).
After treatment of 11 patients, the first interim analysis
was performed in September 2010, and the study would
continue with inclusion of additional 19 patients if feasi-
bility could be shown. After this planned interim
analysis, the protocol was amended on the evidence of
new available data for the combination therapy with
cisplatin and gemcitabine. In detail, the second cohort of
patients received gemcitabine at 1000 mg/m2 and
cisplatin at 25 mg/m2 on days 1 and 8 every 21 days for
a total of 8 cycles (24 weeks of treatment in total). The
treatment was stopped ahead of schedule in case of
unacceptable toxicities, tumor recurrence, or patient
wish. If the administration of the planned chemotherapy
was delayed for more than a month, the treatment was
discontinued and the patient clinically followed there-
after. Blood examinations were performed on each day
of treatment. To continue treatment as planned, a neu-
trophil count greater than 1000/μl, and a platelet count
greater than 100,000/μl was required for each full dose
of gemcitabine and cisplatin. Dose reductions were indi-
cated at days 8 (combined regimen cohort) or 15 (single
agent cohort) of each cycle in case of thrombocytopenia
Fig. 1 Enrollment, treatment group 1 and group 2
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with platelets between 75,000 and 100,000/μl and/or
absolute neutrophil counts between 500 and 1000/μl.
The treatment was withheld if neutrophil count was
below 500/μl or platelet count was below 75,000/μl.
Treatment was restarted following hematologic recovery
(neutrophil >1000/μl and/or platelets >100,000/μl,
respectively. Administration of G-CSF was allowed, but
discontinuation was required at least 2 days prior to the
next administration of chemotherapy.
After end of treatment clinical visits and laboratory
analyses were carried out every three months for the
first two years, thereafter every 6 months for the next
three years and thereafter at the discretion of the attend-
ing physician. Assessments with CT-scans of thorax and
abdomen and/or MRI of the abdomen were performed
after end of treatment and 6 months later, and thereafter
at the discretion of the attending physician.
Statistical analysis
Patient recruitment followed a Simon’s two-stage design;
a maximum of anticipated non-laboratory adverse events
≥ grade 3 in up to 45% of patients was considered
acceptable, whereas non-laboratory adverse events ≥
grade 3 in more than 70% were considered unacceptable,
resulting in the regimen being considered not feasible.
Eleven patients had been planned to be recruited in the
first phase; and if 4 or fewer patients experience at least
one Grade 3 or 4 non-laboratory toxicity, a further 19
patients would be recruited for a total of 30 evaluable
patients. This study had 80% power to discriminate be-
tween these two levels at the 5% level of significance.
The relative dose intensity (RDI) was calculated as the
ratio of the actual dose given during the study to the
planned dose in the protocol. DFS would be calculated
from the day of resection until locoregional recurrence,
the development of distant metastases, second primary
cancer, death from the same or other cancer, or
treatment-related death. Overall survival was calculated
from the day of resection until death. Follow-up is also
being reported from the day of surgery until the final
cut-off date at 31st December 2016. Patients alive would
be censored at that time point. Continuous and ordinal
variables were presented as median with interquartile
range (IQR). DFS and OS were determined by the
Kaplan-Meier method and Cox-regression. Median time
to event was reported with 95% confidence interval (CI).
Estimates at 3 years were presented with standard error.
Hazard ratios (HR) of gemcitabine plus cisplatin vs.
gemcitabine monotherapy were presented with 95% CI.
A post hoc comparison of the two patient groups receiv-
ing either gemcitabine alone or combination therapy
with cisplatin and gemcitabine was performed by the
log-rank test.
Results
Patient characteristics
From August 2008 to December 2014, 33 patients who
underwent resection for BTC were screened for inclusion
into this study, and 30 patients were finally enrolled.
Reasons for non-enrolment were diagnosis of small cell
carcinoma of the gallbladder, postoperative infectious
complications and early relapse of disease, and early start
of palliative chemotherapy due to a macroscopic R2 resec-
tion. Of the five patients with gallbladder cancer, one had
an incidental finding of cancer after cholecystectomy and
underwent a completion oncological resection. The demo-
graphic and clinical characteristics of the 30 patients are
shown in Table 1. Major postoperative complications were
observed in four patients: a pancreatic fistula in one
patient, a liver abscess in one patients, and two patients
developed a bilioma, with one of these patients
undergoing a bilioenteral neostomy and percutaneous
transhepatic cholangiography and drainage (PTCD).
Table 1 Patient characteristics (n = 30)
Characteristic No. (%)
Age Median (IQR)
55.5 (51–65.5)
Gender
Male 14 (47)
Female 16 (53)
ECOG Performance Status
ECOG PS 0 21 (70)
ECOG PS 1 9 (30)
Tumor localization
Extrahepatic 6 (20)
Intrahepatic 17 (57)
Gallbladder 5 (17)
Ampulla vateri 2 (7)
Stage TNM
T1/T2/T3/T4 4 (13)/15 (50)/11 (37)/0 (0)
N0/1 20 (67)/10 (33)
Margin Status
R0 28 (93)
R1 2 (7)
Operative Procedurea
Major hepatectomy 17 (57)
Hepatopancreaticoduodenectomy 1 (3)
Gall bladder bed resection 9 (30)
Pancreaticoduodenectomy 5 (17)
Time of initiation of Chemotherapy (days) Median (IQR) 49.5 (39.8–64.5)
Abbreviations: IQR Interquartile Range, ECOG Eastern Cooperative Oncology
Group, TNM tumor node metastasis, R residual tumor after treatment
aIncludes multiple counts
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All patients recovered by the time of starting chemother-
apy. Treatment was initiated after a median of 50 days
(IQR 40–65 days) after curative intent surgery.
Feasibility
After treatment of 11 patients the planned interim safety
analysis was performed. Two patients in this group had
to be excluded from analysis, as one patient could not
start chemotherapy due to postoperative infectious com-
plications and early relapse of disease. The second
patient had a macroscopic R2 resection. Overall, 9 pa-
tients were analysed. Treatment was well tolerated.
However non-hematologic adverse events of grade 3 and
4 developed during treatment in 3 patients (33%). Two
patients (22%) developed hypertension grade 3, which
was controlled with antihypertensive medication, and
one patient had a self-limiting episode of dyspnea grade
3 (11%), explained by concomitant anemia (grade 3).
After recovery of the hemoglobin levels the dyspnea re-
solved. As all these non-hematologic adverse events
were self-limiting or medically controlled without the
need for hospitalization, we considered the treatment
feasible and safe. As the results of the ABCstudy [16]
had been reported at that time, demonstrating similar
rates of adverse events for gemcitabine alone and the
combination of gemcitabine and cisplatin, we considered
adding cisplatin to the gemcitabine treatment safe and
completed recruitment with the combination regimen
after protocol amendment. Thus, the study was contin-
ued at September 2010, and 22 additional patients were
enrolled. One of the subsequently enrolled patients was
diagnosed with small cell cancer of the gallbladder and
was subsequently excluded from the analysis.
The median time to onset of chemotherapy after sur-
gery was 48 days (IQR 38.5–56.5) in the gemcitabine
monotherapy group, and 54 days (IQR 39.5–70.5) in the
cisplatin-gemcitabine group, respectively. Completion
rates were 98% among the gemcitabine monotherapy
treated patients, and 81% for cisplatin and 87% for gem-
citabine in the combination treatment group (Table 2).
The median RDI of gemcitabine delivered in the mono-
therapy group was 100% (IQR 91–100).
Patients with the combination of cisplatin-gemcitabine
showed a median dose intensity of 100% (IQR 50–100)
for cisplatin and 100% (IQR 75–100) for gemcitabine
(Table 3).
In the gemcitabine monotherapy group, treatment was
discontinued in one patient because of not further speci-
fied recurrent abdominal infections and pulmonary fistula.
In the cisplatin-gemcitabine combination group treatment
was discontinued ahead of schedule in 9 patients due to
following reasons: neuropathy (n = 1), early tumor recur-
rence (n = 1), fatigue (n = 2), renal impairment (n = 2), sep-
tic shock and death (n = 1), and hematologic adverse
events (n = 2).
Adverse events
Hematologic and non-hematologic adverse events of
grade 3 and 4 are listed in Table 4. The main adverse
events were hematologic toxicities with leukopenia
(27%) and neutropenia (50%). Anemia was documented
Table 2 Comparison of treatments in the gemcitabine-only and
cisplatin-gemcitabine group
Group 1
(n = 9, GEM)
Group 2
(n = 21, CIS/GEM)
Time of initiation days; median (IQR) 48 (38.5–56.5) 54 (39.5–70.5)
Number of courses; median 6 8/8
Completion rate; % 98% 81%/88%
Dose reduction; no. 7 15
Abbreviations: GEM gemcitabine, CIS cisplatin, IQR interquartile range
Table 3 Relative dose intensity (RDI) for the two treatment regimens
Dose Intensity Rates (DSI) in percentage
GEM Group (n = 9) CIS/GEM Group (n = 21)
CIS GEM
Cycles Median IQR Cycles Median IQR Median IQR
C1 100 (91.7–100) C1 100 (100–100) 100 (100–100)
C2 100 (95–100) C2 100 (100–100) 100 (100–100)
C3 100 (90.9–100) C3 100 (70–100) 100 (76.4–100)
C4 100 (86.7–100) C4 80 (50–100) 100 (77.5–100)
C5 100 (95–100) C5 80 (50–100) 100 (70–100)
C6 100 (88.9–100) C6 80 (25–100) 94.1 (70–100)
C7 50 (0–100) 88.9 (56.3–100)
C8 50 (0–90) 75 (50–100)
Overall DSI 100 (91–100) 100 (50–100) 100 (75–100)
Abbreviations: GEM gemcitabine, CIS cisplatin, IQR interquartile range, C cycles
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in 10% and thrombocytopenia in 17% in total for both
groups. Mentionable non-hematologic toxicities of grade
3 and 4 were fatigue in 6 (20%) patients and infections
in three (10%) patients. Infections were only seen in the
cisplatin-gemcitabine group. Two patients (7%) receiving
the combination treatment developed biliary sepsis.
Renal dysfunction was observed in two patients (7%) re-
ceiving the combination. One treatment-related death
was observed in a patient who developed a septic shock
due to a pulmonary infection during the second cycle of
cisplatin and gemcitabine. Overall, non-hematological
adverse events grade 3 or greater related to chemother-
apy were observed in 11 (37%) patients during treat-
ment, in three (33%) patients receiving gemcitabine
alone and in eight (38%) patients receiving cisplatin plus
gemcitabine.
Survival
The median follow-up time was 31.4 months (IQR,
23.2–49.5 months) at the time of data cut-off. Eleven pa-
tients were still alive at this time point. The median DFS
was 14.9 months (95% CI 0–33.8) for the entire patient
population with a 3-year DFS of 43.1 ± 9.1%. (Fig. 2).
The median DFS of the patients receiving gemcitabine
plus cisplatin was 28.8 months (95% CI not available),
and 14.4 months (95% CI 9.5–19.3) in the patients re-
ceiving gemcitabine alone (Fig. 3). No differences were
seen in an exploratory post hoc comparison (HR 0.57
(95% CI 0.23–1.4); p = 0.22) between the two treatment
groups.
Table 4 Grade 3 and 4 adverse events. Reported is the highest
grade observed
Eventsa Grade 3 - 4b
GEM (n = 9)
Grade 3 - 4b
CIS/GEM (n = 21)
Total
No. (%)
Hematologic toxic effects
Leukopenia 0 8 (38) 8 (27)
Neutropenia 3 (33) 12 (57) 15
(50)
Thrombocytopenia 1 (11) 4 (19) 5 (17)
Anaemia 0 3 (14) 3 (10)
Non-hematologic toxic effects
Alopecia 0 2 (10) 2 (7)
Anorexia 0 2 (10) 2 (7)
Fatigue 3 (33) 4 (19) 6 (20)
Nausea 0 1 (5) 1 (3)
Vomiting 0 1 (5) 1 (3)
Impaired renal function 0 2 (5) 2 (7)
Infection 0 (0) 3 (14) 3 (10)
Without neutropenia 0 0 0 (0)
With neutropenia 0 3 3 (10)
Biliary sepsis 0 2 2 (7)
Deep-vein thrombosis 0 1 (5) 1 (3)
Other 1 (11) 5 (24) 6 (20)
Liver function
Increased ALAT level 0 1 (5) 1 (3)
Other abnormal liver
functionc
0 2 (10) 2 (7)
Any abnormal liver functiond 0 0 (0) 0 (0)
Abbreviations: GEM gemcitabine, CIS cisplatin, ALAT alanine aminotransferase
aMultiple adverse events per patient possible
bPre-existing conditions are reported only in case of worsening during
study treatment
cElevated gamma-GT
dHypoalbumia, decreased Vitamin K level
Fig. 2 Cumulative disease free survival curve of the study population
(n = 30). The median DFS was 14.9 months (95% CI 0–33.8) for the
entire patient population with a 3-year DFS of 43.1 ± 9.1%
Fig. 3 Disease free survival of gemcitabine-mono (blue curve) and
cisplatin-gemcitabine (green curve) patients. The median DFS of the
patients receiving gemcitabine plus cisplatin was 28.8 months (95%
CI not available), and 14.4 months (95% CI 9.5–19.3) in the patients
receiving gemcitabine alone
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The median overall survival of the whole patient col-
lective was 40.6 month (95% CI 18.8–62.3) with a 3-year
OS of 55.7 ± 9.2% (Fig. 4). Patients receiving cisplatin
plus gemcitabine had a median OS of 36.9 months (95%
CI 22.1–51.7), and patients receiving gemcitabine alone
had a median survival of 46.9 months (95% CI 17.5–
76.3) (Fig. 5). No statistically significant difference was
seen between the two groups in a post hoc comparison
(HR 0.82 (95% CI 0.32–2.1); p = 0.67).
Treatment after tumor recurrence
Overall, 18 tumor recurrences were observed until end
of follow-up. Local, distant, and combined local and
distant recurrences were seen in 9, 3, and 6 patients,
respectively. Patients initially treated with gemcitabine
alone were offered the combination of cisplatin plus
gemcitabine at the time of recurrence. Patients who suf-
fered tumor recurrence during or after treatment within
the cisplatin-gemcitabine cohort were offered various
treatment regimens, chosen according to the perform-
ance status of the patients. Treatment consisted of FOL-
FIRINOX, FOLFOX, FOLFIRI or, in later lines, cisplatin-
etoposide or carboplatin-etoposide. One patient received
cetuximab combined with fluorouracil, oxaliplatin and
leucovorine. Three patients with local recurrences re-
ceived selective intraarterial radiotherapy (SIRT). One
patient received radiochemotherapy with capecitabine.
No patient was able to undergo secondary resection.
Discussion
This prospective phase II study was able to document
the feasibility of adjuvant chemotherapy with gemcita-
bine alone or combined with cisplatin in patients after
curative intent surgery for BTC. Assessment of safety
was our primary objective, as patients frequently have to
cope with postoperative complications like fatigue, hepa-
tobiliary infections and impaired renal or liver function
after major liver resection. The number of patients
developing higher grades of non-hematological adverse
events during treatment did not exceed the predefined
cut-off, and adjuvant chemotherapy was thus deemed
safe. With a median follow up time of 31 months we
were able to record a 3-year DFS of 43% and a 3-year
OS of 56% in our patient population. These data are well
in line with recently published retrospective analyses,
which suggest a survival advantage from adjuvant
chemotherapy [17–21].
Our data highlight that single agent gemcitabine and
the combination of cisplatin plus gemcitabine are both
feasible options for adjuvant treatment of patients who
had undergone macroscopic complete resection of bil-
iary tract cancer. Hematologic adverse events like neu-
tropenia were more frequently noted in the combination
group than in the gemcitabine monotherapy group (63%
vs 27%), and, accordingly, also higher rates of infections
were seen with the combination treatment (16% vs. 9%).
One explanation for this finding may be that the preced-
ing hepatobiliary resection may result in subsequent
postoperative complications like fistulation or biliomas,
which predispose the patients toward infectious compli-
cations per se. This high rate of infectious complications
in the combination regimen cohort highlights that pa-
tient recovery after surgery is of utmost importance and
needs to be achieved before potentially hematotoxic
chemotherapy can be administered. Despite the fact that
we were not able to start adjuvant treatment in all
patients within the anticipated eight-week interval after
resection due to delayed recovery time, the RDI was
Fig. 4 Cumulative overall survival curve of the study population
(n = 30). The median overall survival of the whole patient collective
was 40.6 month (95% CI 18.8–62.3) with a 3-year OS of 55.7 ± 9.2%
Fig. 5 Overall survival of gemcitabine-mono (blue curve) and
cisplatin- gemcitabine (green curve) patients. Patients receiving
cisplatin plus gemcitabine had a median OS of 36.9 months (95% CI
22.1–51.7), and patients receiving gemcitabine alone had a median
survival of 46.9 months (95% CI 17.5–76.3)
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rather high in both patient cohorts, underscoring the
feasibility of adjuvant chemotherapy in this patient
population. Median RDI of 100% could be reached with
gemcitabine alone and the cisplatin-gemcitabine com-
bination as well, demonstrating very good tolerability of
both regimens in the post-operative adjuvant setting.
The optimal adjuvant management of patients under-
going curative intent resection of BTC has not been
defined as of completion of this study. Several practice
guidelines, i.e. by ESMO and NCCN, are in place, which
recommend the use of adjuvant chemotherapy with
platinum based chemotherapy or chemoradiation in the
adjuvant setting within clinical trials [22]. However,
these recommendations are based predominantly on
retrospective data, small series or personal practice.
Only few prospective trials studying the role of adju-
vant treatment combining gemcitabine with another
chemotherapeutic partner are available [23–25]. They
evaluated the feasibility of these regimens in predomin-
antly Asian patient populations and reported similar
survival outcome as in the present study.
A few randomized phase III trials are currently being
conducted and are assessing the impact of different
chemotherapy regimens after macroscopically complete
resection of BTC [26, 27]. One phase III study evaluating
gemcitabine in combination with oxaliplatin (PRODIGE
12) showed that the combination chemotherapy was
feasible, but found no difference in relapse free survival
compared to the observation group [28]. A second phase
III study (BILCAP) testing single agent capecitabine in
the adjuvant setting was recently reported and showed,
in contrast to the aforementioned PRODIGE 12, a signal
in favour of adjuvant chemotherapy [29]. Although the
study failed to demonstrate a significant improvement of
overall survival in the intention to treat analysis, the
median survival was markedly longer if patients were
treated with capecitabine as per protocol [30]. The
better outcome may be attributed to a higher number of
patients with nodal-positive disease included in the latter
study compared to the PRODIGE 12. This explanation is
being supported by a statistically significant difference in
overall survival after adjusting for various risk factors,
including nodal status, in a prespecified sensitivity ana-
lysis of the BILCAP study, suggesting that these patients
may derive the most benefit from adjuvant chemother-
apy. Based on these results, adjuvant capecitabine may
evolve into a new practice standard after curative
resection of BTC. Finally, a large multi-national study
(ACTICCA-1) is evaluating the combination of gemcita-
bine plus cisplatin with results being expected in the
next years. As our study was planned and set up before
this phase III trial had been initiated, we are able to pro-
vide valuable information on the feasibility and efficacy
of adjuvant gemcitabine and cisplatin in patients with
resected cholangiocarcinoma at a time when no other
data are available for this doublet. As extrahepatic
BTC may have a different biological behaviour than
intrahepatic cancers, a subgroup analysis would be
desirable to evaluate which patients may derive the
most benefit of this doublet regimen. If we look at
the large ABC-02 trial, the addition of cisplatin to
gemcitabine resulted in a comparable advantage in
terms of survival for all subgroups of patients, irre-
spective of the origin of the biliary tumor, suggesting
that all patients with BTC may achieve a benefit from
this combination. The results of the ACTICCA-1
study and further analyses of the BILCAP study will
hopefully identify subsets of patients who may benefit
in particular from a specific regimen.
Our study has some limitations. First, due to the low
number and the heterogeneity of patients included, this
study was not sufficiently powered to allow meaningful
subgroup analyses, for instance with regard to nodal or
resection margin positivity and the aforementioned
tumor localization. Our post hoc comparison of the two
treatment groups is therefore only exploratory. Second,
the study was planned and conducted at a single institu-
tion in Switzerland. As cholangiocarcinoma is still to be
considered a rather rare disease compared to pancreatic
cancer, patient availability for enrolment into this study
was too low to allow for a rapid completion within a few
years. In addition, the study had to be amended to adapt
the treatment regimen, and halting the patient accrual
for some months was necessary, which further delayed
the completion of the study. Being confronted with these
barriers, we were able to establish a patient referral
system with various regional centers for this specific
study, which improved accrual rates and helped to finish
the study.
Conclusions
In conclusion, our study showed that treatment with gem-
citabine either alone or combined with cisplatin is feasible
and well tolerated in patients with curative resected biliary
tract cancer. Toxicities were within the expected range,
and survival rates were promising. The multi-national
prospective phase III trial ACTICCA-1 addressing the
question of adjuvant gemcitabine and cisplatin is currently
underway and will help to identify the optimal regimen
for this difficult to treat patient population.
Abbreviations
ALAT: alanine aminotransferase; C: Cycles; CIS: Cisplatin; ECOG: Eastern
Cooperative Oncology Group; GEM: Gemcitabine; HPD: Hepatectomy
concomitant with pancreatoduodenectomy; IQR: Interquartile Range;
R: Residual tumor after treatment; TNM: Tumor node metastasis
Acknowledgements
We thank the following centers in Switzerland for their support: Cantonal
Hospital Chur; Cantonal Hospital Glarus; Cantonal Hospital Winterthur;
Siebenhüner et al. BMC Cancer  (2018) 18:72 Page 8 of 10
Hôpital du Valais,Sion; Hospital Bülach; Cantonal Hospital Uri; Cantonal
Hospital Münsterlingen; Hospital Wetzikon
Funding
The authors have no support or funding to report.
Availability of data and materials
The dataset generated and analyzed during the current study is available
from the corresponding author on reasonable request.
Authors’ contributions
AS: treated patients, collected data, analyzed data, provided administrative
support, wrote the manuscript, gave final approval of the version submitted.
HS: treated patients, collected data, gave final approval of the version
submitted. HB: collected data, analyzed data, provided administrative
support, gave final approval of the version submitted. BS: study design,
analyzed data, provided administrative support, gave final approval of
the version submitted. TW: treated patients, collected data, gave final
approval to the version submitted. JF: treated patients, collected data,
gave final approval to the version submitted. SB: treated patients,
collected data, gave final approval to the version submitted. PAC: study
design, treated patients, gave final approval of the version submitted.
RS: provided administrative support, treated patients, analyzed data, gave
final approval of the version submitted. AK: study design, provided
administrative support, gave final approval of the version submitted.
BP: study design, treated patients, collected data, analyzed data,
provided administrative support, gave final approval of the version
submitted. PS: study design, treated patients, collected data, analyzed
data, provided administrative support, wrote the manuscript, gave final
approval of the version submitted.
Ethics approval and consent to participate
The study was conducted after obtaining approval from the local ethical
committee (ethical number KEK Zurich 1442) at 15th January 2008 and
Swissmedic by 2nd April 2008. First patient was included at 4th August 2008.
Written informed consent was obtained from all patients in accordance with
the Declaration of Helsinki. The study was registered at clinicaltrials.gov
(NCT01073839). The study was retrospectively registered on 25th June 2009
at clinicaltrials.gov, as it was not yet obligatory at the time of trial start
according to national specifications.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medical Oncology, University Hospital Zurich, Rämistrasse
100, 8091 Zurich, CH, Switzerland. 2Swiss HBP Center, University Hospital
Zurich, Rämistrasse 100, 8091 Zurich, CH, Switzerland. 3Epidemiology,
Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84,
8001 Zurich, CH, Switzerland. 4National Center for Cancer Care and Research,
Doha, Qatar. 5Department of Surgery, Cantonal Hospital of Winterthur,
Brauerstrasse 15, 8401 Winterthur, Switzerland.
Received: 28 August 2017 Accepted: 21 December 2017
References
1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC.
Changing international trends in mortality rates for liver, biliary and
pancreatic tumours. J Hepatol. 2002;37(6):806–13.
2. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in
cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise.
Oncologist. 2016;21(5):594–9.
3. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and
management of intrahepatic cholangiocarcinoma. J Hepatol.
2014;60(6):1268–89.
4. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and
treatment of cholangiocarcinoma: consensus document. Gut.
2002;51(Suppl 6):VI1–9.
5. Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic
options. World J Gastroenterol. 2015;21(43):12211–7.
6. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T.
Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-
fluorouracil alone in the treatment of pancreatic-biliary carcinomas.
Oncology. 1994;51(5):396–400.
7. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy
with fluorouracil plus folinic acid or gemcitabine vs observation on survival
in patients with resected periampullary adenocarcinoma: the ESPAC-3
periampullary cancer randomized trial. JAMA. 2012;308(2):147–56.
8. Kwon J, Kim BH, Kim K, Chie EK, Ha SW. Survival benefit of adjuvant
Chemoradiotherapy in patients with ampulla of Vater cancer: a systematic
review and meta-analysis. Ann Surg. 2015;262(1):47–52.
9. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of
biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol.
2012;30(16):1934–40.
10. McNamara MG, Walter T, Horgan AM, et al. Outcome of adjuvant therapy in
biliary tract cancers. Am J Clin Oncol. 2015;38(4):382–7.
11. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and
clinical benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc
Clin Oncol. 1997;15(6):2403–13.
12. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with
gemcitabine and long-term outcomes among patients with resected
pancreatic cancer: the CONKO-001 randomized trial. JAMA.
2013;310(14):1473–81.
13. Verderame F, Mandina P, Abruzzo F, Scarpulla M, Di Leo R. Biliary tract
cancer: our experience with gemcitabine treatment. Anti-Cancer Drugs.
2000;11(9):707–8.
14. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M, Phase II. Study of
systemic gemcitabine chemotherapy for advanced unresectable
hepatobiliary carcinomas. Hepato-Gastroenterology. 2001;48(39):783–9.
15. Kiba T, Nishimura T, Matsumoto S, et al. Single-agent gemcitabine for biliary
tract cancers. Study outcomes and systematic review of the literature.
Oncology. 2006;70(5):358–65.
16. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
17. Schweitzer N, Weber T, Kirstein MM, et al. The effect of adjuvant
chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched
pair analysis. J Cancer Res Clin Oncol. 2017;143(7):1347–55.
18. Kim YS, SY O, Go SI, et al. The role of adjuvant therapy after R0 resection for
patients with intrahepatic and perihilar cholangiocarcinomas. Cancer
Chemother Pharmacol. 2017;79(1):99–106.
19. Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R. Impact of
adjuvant chemoradiation on survival in patients with resectable
cholangiocarcinoma. HPB (Oxford). 2016;18(10):843–50.
20. Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy
for resectable perihilar cholangiocarcinoma with lymph node involvement:
a propensity score matching analysis. Surg Today. 2017;47(2):182–92.
21. Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant
chemotherapy improves survival after aggressive surgery for hilar
cholangiocarcinoma. J Gastrointest Surg. 2009;13(8):1470–9.
22. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary
cancer: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2016;27(suppl 5):v28–37.
23. Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of
gemcitabine plus cisplatin combination therapy after curative resection for
biliary tract cancer. J Hepatobiliary Pancreat Sci. 2015;22(11):789–94.
24. Toyoda M, Ajiki T, Fujiwara Y, et al. Phase I study of adjuvant chemotherapy
with gemcitabine plus cisplatin in patients with biliary tract cancer
undergoing curative resection without major hepatectomy (KHBO1004).
Cancer Chemother Pharmacol. 2014;73(6):1295–301.
Siebenhüner et al. BMC Cancer  (2018) 18:72 Page 9 of 10
25. Cho M, Wang-Gillam A, Myerson R, et al. A phase II study of adjuvant
gemcitabine plus docetaxel followed by concurrent chemoradation in
resected pancreaticobiliary carcinoma. HPB (Oxford). 2015;17(7):587–93.
26. Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with
gemcitabine and cisplatin compared to observation after curative intent
resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma
(ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III
trial. BMC Cancer. 2015;15:564.
27. Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for
cholangiocarcinoma: an update. World journal of gastrointestinal
oncology. 2013;5(7):171–6.
28. Edeline J, Bonnetain F, Phelip J, et al. Gemox versus surveillance following
surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD
18 (UNICANCER GI) phase III trial. J Clin Oncol. 2017;35(suppl 4S; abstr 225)
29. BILCAP. A randomized clinical trial evaluating adjuvant chemotherapy with
capecitabine compared to expectant treatment alone following curative
surgery for biliary tract cancer. J Clin Oncol. 2011;29(suppl; abstr 4125):4125.
30. Primrose J, Fox R, Palmer D, et al. Adjuvant capecitabine for biliary tract cancer:
The BILCAP randomized study. J Clin Oncol. 2017;35(suppl; abstr 4006):4006.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Siebenhüner et al. BMC Cancer  (2018) 18:72 Page 10 of 10
